Factor V Leiden, factor V Cambridge, factor II GA20210, and methylenetetrahydrofolate reductase in cerebral venous and sinus thrombosis: A case-control study

Autor: Mohammad Saadatnia, Mansour Salehi, Ahmad Movahedian, Seyed Ziaeddin Samsam Shariat, Mehri Salari, Marzieh Tajmirriahi, Elham Asadimobarakeh, Rasoul Salehi, Gilda Amini, Homa Ebrahimi, Ehsan Kheradmand
Jazyk: angličtina
Rok vydání: 2015
Předmět:
Zdroj: Journal of Research in Medical Sciences, Vol 20, Iss 6, Pp 554-562 (2015)
Druh dokumentu: article
ISSN: 1735-1995
1735-7136
DOI: 10.4103/1735-1995.165956
Popis: Background: Factor V G1691A (FV Leiden), FII GA20210, and methylenetetrahydrofolate reductase (MTHFR) C677T mutations are the most common genetic risk factors for thromboembolism in the Western countries. However, there is rare data in Iran about cerebral venous and sinus thrombosis (CVST) patients. The aim of this study was to evaluate the frequency of common genetic thrombophilic factors in CVST patients. Materials and Methods: Forty consequently CVST patients from two University Hospital in Isfahan University of Medical Sciences aged more than 15 years from January 2009 to January 2011 were recruited. In parallel, 51 healthy subjects with the same age and race from similar population selected as controls. FV Leiden, FII GA20210, MTHFR C677T, and FV Cambridge gene mutations by polymerase chain reaction technique were evaluated in case and control groups. Results: FV Leiden, FII GA20210, and FV Cambridge gene mutations had very low prevalence in both case (5%, 2%, 0%) and control (2.5%, 0%, 0%) and were not found any significant difference between groups. MTHFR C677T mutations was in 22 (55%) of patients in case group and 18 (35.5%) of control group (P = 0.09). Conclusion: This study showed that the prevalence of FV Leiden, FII GA20210, and FV Cambridge were low. Laboratory investigations of these mutations as a routine test for all patients with CVST may not be cost benefit.
Databáze: Directory of Open Access Journals
Externí odkaz: